By Chris Wack
Serina Therapeutics shares were up 24% to $5.88 in premarket trading after the company said it secured $10 million in equity financing from strategic shareholder JuvVentures (UK) Limited.
The clinical-stage biotechnology company said the transaction provides it with funding to continue advancing its lead candidate SER-252 into a Phase 1 clinical trial in advanced Parkinson's disease patients in the second half of 2025.
Under the terms of the funding agreement, Serina will issue 1 million shares at $10 a share, a 120% premium to the closing price on Nov. 26.
The financing will be delivered in two tranches. The first tranche of $5 million was received Nov. 27, and the second $5 million tranche will be delivered by Jan. 31.
Serina's SER-252 is an investigational therapy developed for advanced Parkinson's patients.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
December 03, 2024 06:44 ET (11:44 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.